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Background: Currently available biomarkers for the early tissue process leading to joint damage in rheumatoid arthritis
are insufficient and lack prognostic accuracy, possibly a result of variable activity of the disease over time. This study
represents a novel approach to detect an altered activity of the disease process detected as increasing serum-COMP
levels over a short time and whether this would correlate with joint damage progression over the first 5 years of disease.
Methods: In all, 349 patients from the Swedish BARFOT early RA study were examined. Serum-COMP was analysed by
ELISA at diagnosis and after 3 months. Based on changes in serum-COMP levels, three subgroups of patients were
defined: those with unchanged levels (change ≤ 20%) (N=142), decreasing levels (> 20%) (N=173) and increasing levels
(> 20%) (N=34). Radiographs of hands and feet were obtained at inclusion, after 1, 2 and 5 years and scored according
to Sharp van der Heijde (SHS). Radiographic progression was defined as increase in SHS by ≥5.8.
Results: The group of patients with increasing COMP levels showed higher median change in total SHS and erosion
scores at 1, 2 and 5 year follow-up compared with the groups with stable or decreasing COMP levels. Furthermore, the
odds ratio of radiographic progression was 2.8 (95% CI 1.26-6.38) for patients with increasing COMP levels vs. patients
with unchanged levels.
The group of patients with increasing COMP levels had higher ESR at inclusion but there were no baseline differences
between the groups for age, gender, disease duration, disease activity (DAS28), function (HAQ), CRP, nor presence of
rheumatoid factor or anti-CCP. Importantly, neither did changes over the 3-month period in DAS28, HAQ, ESR nor CRP
differ between the groups and these variables did not correlate to joint damage progression.
Conclusion: Increasing serum-COMP levels between diagnosis and the subsequent 3 months in patients with early RA
represents a novel indicator of an activated destructive process in the joint and is a promising tool to identify patients
with significant joint damage progression during a 5-year period.
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progressionBackground
Rheumatoid arthritis (RA) is a heterogeneous disease with
a markedly variable course in different patients. A major
challenge for the treating physician is to early upon diag-
nosis identify patients prone to different outcomes. In
view of new developments in pharmacotherapy, it would
be optimal to early identify those patients who are likely* Correspondence: maria.andersson@spenshult.se
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distribution, and reproduction in any mediumto develop a severe disease and enroll them for early ag-
gressive treatment. On the other hand, with reliable prog-
nostic indicators patients who have a potentially mild
disease could be spared therapy associated with risks of
side effects.
Disease outcome can be defined in different ways, i.e.
radiographic joint damage, functional disability or mortal-
ity. Obviously these variables are interlinked, but predictors
are not entirely overlapping [1]. However, radiographic
outcome may be considered a key variable since it reflectstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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process in bone and cartilage and accounts for a great deal
of the disability in RA [2-4]. In search of prognostic makers
to select patients for early intervention, there is little for
the individual patient, while indicators that tell us that a
cohort of patients has a higher risk, have been identified
providing promise for future work. It is reasonably well
established that some clinical and serological variables i.e.
female sex, early joint erosions, presence of rheumatoid
factor and/or anti-cyclic citrullinated peptide (Anti-CCP)
and high inflammatory activity as measured by e.g. C-
reactive protein (CRP) are negative prognostic signs, but
the utility of these is limited when applied on an individual
patient basis [5-7].
Another approach which is increasingly being explored
is based on the assumption that release of molecules/
fragments from joint tissue into the circulation reflects
ongoing tissue turnover. Increased release should indi-
cate accelerated turnover possibly with an emphasis on
degradation and if persistent lead to permanent joint
damage [8]. This forms the rationale for applying tissue
markers to identify patients prone to rapid joint damage
progression and to distinguish them from those having a
more favourable prognosis.
One such biomarker is cartilage oligomeric matrix pro-
tein (COMP, thrombospondin 5). COMP is a 435-kDa
homopentameric, extracellular protein primarily identified
in cartilage [9,10]. Although COMP has also been identi-
fied in smaller amounts in normal ligament, meniscus,
tendon, synovium, and osteoblasts as well as in sclero-
derma skin results from e.g. experimental arthritis clearly
indicate that changes in serum levels of COMP in arthritis
reflect processes in the cartilage [11]. COMP has been
studied as a biological marker for diagnostic and prognos-
tic applications as well as for evaluating treatment effects
both in RA and osteoarthritis (OA) [12-17]. Thus, COMP
serum levels were found to be higher in RA patients with
rapidly progressive disease but the prognostic value of sin-
gle measurements is limited [18-20]. In OA, similar obser-
vations have been made but interestingly in this condition
changes in serum-COMP over a 1 or 3 year period seems
to increase the prognostic utility [21-23]. Furthermore, it
was recently shown that serum-COMP levels have a sub-
stantial genetically determined component, i.e. to as much
as 40%. Thus, in some patients the high levels may not be
pathological, which complicates interpretations [24].
Based on the observations that serum-COMP changes
over time in individual patients with OA minimize the
effects of the inter-individual variation we hypothesised
that early changes in serum COMP during RA may re-
late to future joint damage. The present study examined
this hypothesis in a well-defined prospective cohort of pa-
tients with recent onset RA. Alterations in levels of serum-




This study comprises 349 patients, who were included in
the BARFOT (Better Anti-Rheumatic PharmacOTherapy)
early RA study from November 1993 to June 1999. The
BARFOT-study is a longitudinal observational multicenter
study, where patients were consecutively included after
having been diagnosed with RA according to the American
College of Rheumatology 1987 criteria [25], provided that
they had a disease duration not more than 1 year [26].
After baseline evaluation, regular follow-up assessments
according to a defined study protocol were conducted. The
present study included only patients where blood samples
from inclusion and at 3 months follow up as well as radio-
graphs from inclusion and at five year follow-up were avail-
able. Patients not included (n=124) did not differ from
included patients regarding demographics, treatment, total
SHS, serological or inflammatory markers at inclusion or
at the 5 year follow-up in the observational study.
Clinical disease assessments
Disease activity was measured by the composite index
Disease Activity Score calculated on 28 joints (DAS28)
[27]. Remission was defined either as DAS28 <2.6 [28,29]
(EULAR remission) or according to the recently proposed
EULAR/ACR remission criteria (scores on the tender joint
count, swollen joint count, CRP (in mg/dl), and patient
global assessment (0–10 scale) were all ≤1) [30]. Functional
disability was assessed using the Swedish version of the
Stanford Health Assessment Questionnaire (HAQ) [31].
Biochemical assessments
At inclusion venous blood samples were taken before the
patients started treatment with prednisolone and/or dis-
ease modifying anti-rheumatic drugs (DMARDs) and were
analyzed by routine methods for erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP). Rheumatoid
factor (RF) was measured by an agglutination test where a
positive titre was >1/20. Anti-CCP was analysed using the
Immunoscan-RA ELISA CCP2 test (Euro-Diagnostica,
Malmö, Sweden). A titre above 25 U/ml was regarded as
positive. At inclusion and at follow-up blood samples were
centrifuged at 2000 g and stored at −80°C until analysis.
Frozen serum samples from inclusion and from the
follow-up after three months were thawed and analysed in
parallel, i.e. all samples from one patient in the same plate,
using a sandwich ELISA (AnaMar, Lund). COMP is stable
in thawed and refrozen sera. Some of the samples were
not thawed before analysis and some were thawed and re-
frozen. The detection limit of the assay is <0.1 U/L, and its
intra-assay and inter-assay coefficient is < 5%. Samples
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instructions. All analyses were carried out without know-
ledge of patient characteristics.
Based on changes in serum-COMP over the first 3
months and knowledge of the reference change value
(RCV) of COMP, three groups of patients were defined:
unchanged serum-COMP levels (change ≤ 20%) (group
UnCh), increasing levels (increase > 20%) (group InCr)
and decreasing levels (decrease > 20%) (group DeCr).
Blood samples from the follow-up at 6 months, 1 and 2
years were also analyzed. The RCV value indicates the
limit of the normal variation between intra-individual mea-
surements. Variations 20% or less in serum COMP levels
are regarded as a normal biological variation [32-35].
Radiographic examinations
Plain radiographs of the hands and feet were taken at in-
clusion, after 1, 2 and 5 years. Two readers scored the
radiographs independently in chronological order without
knowledge of treatment assignment or clinical response.
The inter-observer intra-class correlation coefficients be-
tween these two readers were above 0.9 for the erosion,
joint space narrowing and total Sharp scores. Radiographic
damage was scored according to the Sharp method as
modified by van der Heijde (SHS), which includes the
hands and feet and allows for separate calculations of a
total score (range 0–448), an erosion score (range 0–280),
and a joint space narrowing (JSN) score (range 0–168)
[36]. The smallest detectable change in total SHS was 5.8.
Radiographic progression was defined as a change of total
SHS of 5.8 or more [37].
Statistical methods
Statistical analyses were performed using PASW Statistics
18 software. All significance tests were two tailed and con-
ducted at the 0.05 significance level. To test differences be-
tween groups Chi2 test was used for proportions and
Kruskal-Wallis test with post hoc analysis for continuous
variables. A logistic regression analysis was used to deter-
mine whether an increase of serum COMP can predict
joint damage progress over the five first years with the dif-
ferent groups as categorical variables. A multiple logistic
analysis was performed to assess if an increase in serum
COMP, between inclusion and 3 months follow-up, of more
than 20% (InCr) compared to stable levels of serum COMP,
change of 20% or less (UnCh), was an independent factor
of joint damage progression, i.e. change in SHS of more
than 5.8. The multiple logistic analysis were controlled for
gender, age, disease duration, anti-CCP, RF, DMARD and
prednisolone treatment at inclusion.
Ethical approval
Ethical approval was obtained from the Ethics Commit-
tee, Lund University, Gothenburg University, LinköpingsUniversity and Karolinska Institute (LU 398–01, Gbg
282–01, LI 01–263, KI 02–075). The study followed the
guidelines from the Helsinki Declaration. Written con-
sent from the participants was obtained.
Results
Serum COMP and baseline characteristics
At baseline, the median (range) serum-COMP level was
12.7 U/L (4.5-32.0).
Clustering patients according to altered COMP levels
over 3 months, three groups were identified: Group
UnCh, of 142 (41%) patients with no change in serum-
COMP, Figure 1B; group DeCr of 173 (49%) patients with
decreasing serum-COMP-levels, Figure 1C; group InCr,
of 34 (10%) patients with increasing serum-COMP levels
Figure 1D.
Table 1 shows demographic and baseline disease vari-
ables. Except for a higher ESR in group InCr, there were
no statistically significant differences between the groups.
Notably, the groups did not differ regarding presence of
RF or anti-CCP, two putative negative prognostic factors.
At baseline, median serum-COMP differed between the
groups being highest in group DeCr (13.8 U/L) and lowest
in group InCr (9.6 U/L) and intermediate in group UnCh
(11.9 U/L), overall p<0.001, Figure 1A. At three months
the median serum-COMP values were lower in the DeCr
group than in both the other two groups, p<0.001. At
6 months the DeCr group had still a lower median serum-
COMP than both the InCr group (p<0.001) and the UnCh
group (p=0.011), but there was no significant difference
between the UnCh group and the InCr group. At 12
months this pattern persisted. At 24 months there were
no significant differences for serum-COMP between the
groups (p=0.142).
Treatment during the 5-year period
There were no significant differences in DMARD treat-
ment between the groups at 3 or 6 months, 1, 2 or 5 years.
No patient was treated with biologics before the follow-up
visit at 2 years and no difference regarding such treatment
between the groups was apparent during the subsequent 3
years. Treatment with prednisolone differed between the
groups. A larger number of patients in group DeCr were
treated with prednisolone from inclusion to the 24 month
follow-up and fewer patients in group InCr from the 3
months to the 2 year follow-up. At 5 years there were no
differences in this respect between the groups.
Radiographic outcome over 5 years
Radiographic progression after 5 years (change in total
SHS score with 5.8 or more) was significantly more fre-
quent in the InCr group, 71%, than in the other groups,
46% and 46% respectively, overall p=0.022. In the InCr





























































































Figure 1 Median value for serum-COMP over the first 2 years in the groups. (A) shows the median value for serum-COMP over the first 2
years in the groups. The inserts show the individual changes between inclusion and the 3 month follow up in the group with unchanged
serum-COMP levels (UnCh, N=142) (B), the group with decreasing levels (DeCr, N=173) (C) and the group with increasing levels (InCr, N=34) (D).
The median values in the inserts are shown as a horisontal line. For further explanation, see text.
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5 years, Figure 2A. Pair wise comparisons of changes in
erosion score indicated significant differences between
groups. Thus, group InCr showed a greater increase in
erosion score than the other groups at all time points,Table 1 Baseline characteristics at inclusion, median values (r
Group UnCh (N=142) Group InCr (
Age 58 (16–83) 56 (25–83)
Gender (% women) 62 56
Disease duration (months) 6.0 (1–13) 3.5 (1–12)
DAS28 5.4 (0.5-7.9) 5.5 (0.5-8.0)
HAQ 0.9 (0–2.6) 1.3 (0–2.3)
ESR (mm/H) 33 (2–110) 42 (2–140)
CRP (mg/L) 22.0 (4–186) 29.5 (3–159)
RF positive (%) 61 67
Anti-CCP (%) 58 61
COMP (U/L) 11.9 (6.1-26.8) 9.6 (5.6-19.3)
Erosion score 0 (0–44) 0 (0–20)
JSN score 0 (0–40) 0 (0–15)
Total Sharp score 1 (0–84) 2 (0–34)
Group UnCh, patients with unchanged serum-COMP levels from inclusion to 3 mon
Group InCr, increasing serum- COMP levels from inclusion to 3 months follow-up (in
Group DeCr, decreasing serum-COMP levels from inclusion to 3 months follow-up (
*Kruskal-Wallis test, ** Chi2 test.Figure 2A. Similarly, the median change in total SHS was
larger in this group but not statistically significant at all
time points, Figure 2C. There were no significant differ-
ences between the groups regarding change in JSN score
Figure 2B.ange)
N=34) Group DeCr (N=173) All (N=349) P-value*
57 (18–84) 58 (16–84) 0.96
68 64 0.33**
6.0 (1–21) 6,0 (1–21) 0.10
5.1 (2.3-8.1) 5,3 (0,5-8,1) 0.06
0.9 (0–2.5) 0,9 (0–2,6) 0.10
27 (2–115) 31 (2–140) 0.006
19.0 (4–228) 21 (3–228) 0.40
56 59 0.46**
56 57 0.86**
13.8 (4.5-32.0) 12.7 (4.5-32.0) <0.001
0 (0–15) 0 (0–44) 0.68
0 (0–33) 0 (0–40) 0.41
0.25 (0–35) 1 (0–84) 0.52













































































































Figure 2 Median change of erosion score (A), joint space narrowing (JSN) (B) and total Sharp van der Heijde score (SHS) (C) between
inclusion and the 1, 2 and 5 year examinations. Figure 2 shows median change with 75% CI (denoted by vertical lines) of erosion score (A),
joint space narrowing (JSN) (B) and total Sharp van der Heijde score (SHS) (C) between inclusion and the 1, 2 and 5 year examinations. Group
UnCh, patients with unchanged serum-COMP levels from inclusion to 3 months follow-up (change ≤ 20%), Group DeCr, patients with decreasing
serum-COMP levels from inclusion to 3 months follow-up (decrease > 20%) and Group InCr, patients with increasing serum-COMP levels from
inclusion to 3 months follow-up (increase > 20%). P-values denote results of Kruskal-Wallis test between groups at 1, 2 and 5 years.
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increased risk of radiographic joint damage progression
at 5 years compared with group UnCh, OR 2.8 (95% CI
1.26-6.38), p=0.011. Group DeCr did not differ in this re-
spect from group UnCh. The association remained after
controlling for gender, age, disease duration, ESR, anti-CCP,
RF, DMARD and prednisolone treatment at inclusion (OR
3.1 (95% CI 1.2-7.8, p=0.019). There was also an increased
risk for patients positive for anti-CCP (OR 4.9 (95% CI 2.5-
9.7, p<0.001).
Clinical disease course and remission
The clinical disease activity measured by DAS28, HAQ,
ESR and CRP decreased in all groups during the study
period and notably there were no significant differences
between the groups for changes in DAS28, HAQ, ESR
or CRP between inclusion and 3 months, 1-, 2- and 5
years follow-up, respectively, data not shown. There was
also no significant difference in joint count (swollen or
tender) between the groups at any time point. At the five
year follow-up there were no differences between the
groups for these variables, except for ESR which was
higher in the InCr group (p=0.02). There were no differ-
ences at five year follow-up between the groups regard-
ing EULAR or EULAR/ACR remission. The proportion
of patients in EULAR remission was 43% (UnCh group),
34% (InCr group) and 45% (DeCr group), p=0.51, re-
spectively and the proportion in ACR/EULAR remission
was 10%, 6% and 10%, respectively, p=0.81.
Discussion
In this study we have introduced a novel approach to de-
tect in serum samples a destructive process in one or
several affected joints in patients with early RA. The
background knowledge is that turnover in all the carti-
lages in the body is rather constant and typical for the
individual, while changing when there is an activated or
inhibited process in one or few cartilages. Thus, changes
in serum concentrations of a molecule derived from the
cartilage could be an indicator of an altered activity of the
process. We have consequently assessed the relevance of
altered serum concentrations of COMP, as a tool for dem-
onstrating activity in the joint and to determine whether
this could indeed be used as an indicator to signal risk for
progressive joint destruction in RA. We measured the al-
terations in serum COMP from inclusion at early stage
disease and until 3 months in a prospectively monitored
early RA cohort.
By assessing this change in COMP level we could iden-
tify 3 different patient groups with unchanged, decreasing
or increasing serum concentrations of COMP and com-
pared the radiological progression of joint damage in hands
and feet over a 5 year period between these 3 groups. The
important main finding in support of the concept was thatthe small group of patients showing increased serum con-
centrations during the initial 3-month period, i.e. more
than 20% compared to baseline, progressed significantly
more than the other groups and had a more marked in-
crease in erosion score and total SHS score at the 1, 2 and
5 year follow-up, although not significant for total SHS.
The fact that the group with increasing levels was
small is not unexpected, considering that marked joint
damage progression is seen only in a small proportion of
patients with early RA over a 5-year period [38].
Notably, the groups did not differ regarding radiographic
appearance at inclusion although the COMP levels did.
Remarkably, serum COMP was lowest in the group with
the largest progression but there was no association be-
tween baseline S-COMP and radiographic progression as-
sessed according to Sharp van der Heijde at 1, 2 or 5 years
(data not shown). There was also no significant associa-
tions between follow-up S-COMP at any time point and
any clinical or radiographic outcome variable. These find-
ings suggest that a single measurement does not provide a
prognostic value.
Interestingly, those patients with an increasing tissue
turnover activity in the early phase of the process reflected
by COMP release are those who will progress the most.
Other molecular indicators should be tested in a similar
fashion to find out whether this is generally applicable.
It is somewhat surprising that the association between
erosion score and COMP changes was more pronounced
than that between COMP changes and JSN. However,
the cartilage and bone processes seem closely interlinked
[39]. One reason for this finding could be related to the
sensitivity of the scoring system. Thus in clinical trials of
potentially damage protective drugs, differences between
treatment groups are often most marked for the erosion
score [40].
There were essentially no differences between the groups
regarding demographic characteristics and for baseline dis-
ease variables. The only difference was a somewhat higher
ESR in the InCr group, which may reflect a more pro-
nounced inflammatory process in these patients. This is not
unexpected in view of the link between inflammation and
joint damage progression [4,41,42]. However, there were no
differences between the groups regarding changes in ESR
or CRP during the study and the groups were clinically in-
distinguishable at five years. Furthermore, the groups did
not differ regarding presence of RF or anti-CCP, which
clearly suggests that the approach to evaluate prognosis re-
garding progression of joint damage introduced in this re-
port adds to the armamentarium of prognostic indicators
in RA.
It is important to note that the patients were treated
differently with respect to glucocorticoids, i.e. more pa-
tients in the DeCr group were treated with prednisolone.
Glucocorticoids are known to retard joint damage at
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concentrations of COMP [43-46]. Thus the decreasing
COMP levels and less progression of joint damage may be
related to the prednisolone treatment in this subgroup.
A limitation to the study is that we had only access to
serum samples at 0 and 3 months during the first 3
months. Analyses of samples obtained more frequently
may have further strengthened the findings and impor-
tantly, would be advantageous in a clinical setting for
making early treatment decisions.
An important strength of this study is the prospective
setting with regular monitoring of the patients including
radiographic examinations and scoring in a systematic
fashion.
Conclusion
In conclusion, we have shown that analyses of changes
of serum COMP between inclusion and a 3 month fol-
low up in patients with early RA could distinguish pa-
tients with different rates of joint damage progression
over a 5 year period. Patients with increasing COMP con-
centrations showed the most marked progression. This
approach should be further investigated, particularly by
assessing the utility of examining samples obtained over a
shorter time interval which potentially could improve the
sensitivity and clinical feasibility.
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